Compare EEFT & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEFT | DYN |
|---|---|---|
| Founded | 1994 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 1996 | 2020 |
| Metric | EEFT | DYN |
|---|---|---|
| Price | $74.53 | $15.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $96.00 | $38.63 |
| AVG Volume (30 Days) | 798.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.05 | N/A |
| EPS | ★ 6.84 | N/A |
| Revenue | ★ $4,244,200,000.00 | N/A |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $6.29 | N/A |
| P/E Ratio | $10.57 | ★ N/A |
| Revenue Growth | ★ 6.38 | N/A |
| 52 Week Low | $64.34 | $7.01 |
| 52 Week High | $114.25 | $25.00 |
| Indicator | EEFT | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 42.46 |
| Support Level | $72.35 | $14.67 |
| Resistance Level | $76.17 | $19.65 |
| Average True Range (ATR) | 2.75 | 0.95 |
| MACD | 0.47 | 0.02 |
| Stochastic Oscillator | 93.44 | 46.49 |
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.